Abstract. Head and neck squamous cell carcinoma (HNSC) is one of most common types of cancer worldwide, and mRNAs and long non-coding RNAs (lncRNAs) have been identified as prognostic biomarkers in HNSC. In the present study, using gene expression datasets from multiple platforms, survival-associated genes in HNSC were identified. Subsequently, a combination of 17 genes (14 mRNAs and 3 lncRNA) was optimized using random forest variable hunting and a risk score model for HNSC prognosis was developed using a cohort from The Cancer Genome Atlas. Patients with high-risk scores tend to have earlier disease recurrence and lower survival rates, compared with those with low-risk scores. This observation was further validated in three independent datasets (GSE41613, GSE10300 and E-MTAB-302). Association analysis revealed that the risk score is independent of other clinicopathological observations. On the basis of the results depicted in the nomogram, the risk score performs better in 3-year survival rate prediction than other clinical observations. In summary, the lncRNA-mRNA signature-based risk score successfully predicts the survival of HNSC and serves as an indicator of prognosis.
Introduction
Head and neck squamous cell carcinoma (HNSC) is one of the most common types of cancer worldwide (1) . According to a recent study, 108,700 new cases were identified and 56,200 mortalities occurred as a result of HNSC in China in 2015 (2) . The reasons behind HNSC carcinogenesis include smoking and human papilloma virus (HPV) infection (3). The 5-year survival rate of HNSC is estimated to be ~50% (4); although novel treatment methods have been utilized, the survival rate has not improved significantly over recent decades (5) . Therefore, a prognostic model was urgently required.
Non-coding RNAs, particularly long non-coding RNAs (lncRNAs), have been the subjects of considerable attention in recent years, although the abundance of these RNAs is much lower than that of mRNAs (6) . lncRNAs serve crucial roles in various cellular processes in HNSC, including carcinogenesis and progression (6) (7) (8) (9) (10) (11) (12) (13) (14) . Metastasis associated lung adenocarcinoma transcript 1 (MALAT1) was identified as an oncogene, and the high expression of MALAT1 is associated with metastasis and poor survival across different cancer types (15) (16) (17) . Suppression of HOX transcript antisense RNA expression was reported to induce apoptosis and to inhibit proliferation of HNSC cells (18) . In addition to their use as prognostic markers, certain lncRNAs, including growth arrest specific 5, were reported to be participate in treatment response (19) . Chemotherapy drugs, including cisplatin and paclitaxel, have been demonstrated to exert effects on lncRNAs (20) , to a certain extent.
In line with this, lncRNAs and mRNAs significantly associated with survival were identified using Cox univariate regression based on two independent datasets. To facilitate the utilization and to reduce the size of the panel, random forest variable hunting was implemented and 17 lncRNA-mRNAs were used to develop the model, which estimated the survival with risk scores. The risk score was significantly associated with survival in all the training and test datasets involved. Association analyses revealed that the risk score is a prognostic factor that is independent of other clinical observations.
Materials and methods
Raw data pre-processing. The Cancer Genome Atlas (TCGA) expression data evaluated using RNA-seq was downloaded from the TCGA website (http://cancergenome.nih.gov/), the (25) . In the validation datasets, coefficients were locked and the risk score for each sample was calculated. The risk score was calculated using the following formula; where β indicates the coefficients evaluated with gene expression and x i refers to the relative gene expression level.
The risk score of each sample was calculated in each dataset, and the median risk score value of each dataset was used to divide the high-risk and low-risk group.
Statistical analysis. All statistical analyses involved in the present study were implemented on R (https://www.r-project. org/; v3.0.1) platform and R packages. Normalization of Affymetrix raw data was performed using the R package 'affy' (26) using function 'rma'. The survival analysis and Cox proportional hazards model was performed using the R package 'survival' and the random forest for variable hunting performed using the package 'randomForestSRC' (27, 28) . The receiver operating characteristic curves were drawn using R package 'pROC' (25) , and the nomogram was drawn using R package 'rms' (29) .
Results

Identification of 87 survival-associated mRNAs and lncRNAs.
Over-fit often occurs in model development. To avoid this, Cox univariate regression was implement in two independent datasets, TCGA-HNSC (n=407) and GSE41613 (n=97). lncRNAs and mRNAs detected in the two platforms (next-generation sequencing assembly by TCGA and affymetrix HG U133 plus 2) were retained for further analysis. The mRNAs and lncRNAs that were significantly associated with overall survival in the two datasets (Cox univariate regression; P<0.01) were retained for further analysis. In total, 87 genes, including 10 lncRNAs and 77 mRNAs, were identified. To reduce redundancy, a random forest variable hunting algorithm was implemented to optimize the panel of lncRNAs and mRNAs. Finally, 17 genes (14 mRNAs and 3 lncRNAs) were identified (Fig. 1A ). The coefficients of 8 genes were negative and those of 9 other genes were positive (Fig. 1B) . The Cox univariate regression and multivariate regression parameters are presented in Table I . . The risk score for each patient was calculated, and the samples were divided into high-risk and low-risk groups using the median risk scores of the TCGA-HNSC samples as cut-off values. The OS times of the high-risk group were significantly (P<0.05) shorter than that of the low-risk group (Fig. 2A) . The recurrence-free survival rate was also evaluated in TCGA-HNSC dataset, with the results demonstrating that the high-risk group exhibited significantly shorter recurrence-free survival (RFS) times (Fig. 2B) . The high-risk group samples tend to have lower survival rates, high expression of oncogenes and low expression of tumor suppressor genes (Fig. 2C) . In order to test the robustness of the risk score, P-values were calculated by retrieving 80% of samples from the dataset (K-fold), and this process was repeated 10,000 times. In 92.59% of cases, the difference in survival rate between the risk-high and risk-low groups was statistically significant, as depicted in Fig. 2D .
Risk-score performance validation. The high performance of the risk score may result from over-fit; thus, the robustness of the risk score was further validated in other independent datasets, GSE41613 (n=97), GSE10300 (n=81) and E-TABM-302 (n=81). Following the locking of coefficients in each dataset, the risk scores were calculated and the high/low-risk groups were divided according to the median risk score in each dataset. The overall survival (OS) and recurrence-free survival (RFS) of the high-risk group were significantly lower than those of the low-risk group (Fig. 3A-C, top) . The expression patterns of these 17 genes in these datasets was similar to those of the training dataset (Fig. 3A-C) . Together, these results indicated that the risk-score staging model was robust across datasets and platforms (RNA-seq and microarray).
To test the performance of random forest variable hunting, which has previously been used for biomarker combination screening (24, 26) , 20 randomly-selected 17-gene panels were generated, and the risk score model was developed using these genes. However, the majority of combinations were not statistically significantly different in the four datasets (17/20; Table II ), indicating that random forest variable hunting is a powerful tool for candidate gene selection.
Risk score and clinicopathological obser vations.
Association analyses between risk score and other clinical observations were performed in the largest dataset, TCGA-HNSC. The results revealed that the risk score was able to predict prognosis independently of sex, differentiation grade and primary tumor size (Fig. 4A) , indicating that the risk score served as an independent prognostic indicator. To facilitate the utilization of the risk score and to evaluate its importance among clinical observations, a nomogram (Fig. 4B) for the 3-year OS rate was plotted, and it was demonstrated that the risk score was the most important predictor of the 3-year OS rate (range, 0-100). Taken together, the aforementioned results indicated that the 17 lncRNA-mRNA-based risk score is an independent clinical indicator and that it is more efficient in predicting survival than other clinical observations. Risk score and radiation therapy. In the present study, patients were artificially divided into radiation-receiving and non-radiation-receiving groups. These groups were further divided into high-risk and low-risk groups based on their corresponding median risk score values. The high-risk group exhibited a significantly poorer survival rate in the radiation-receiving (Fig. 5A ) and non-radiation-receiving groups (Fig. 5B) , indicating that the risk score was a prognostic indicator independent to radiation therapy.
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Discussion
In the present study, using the expression of lncRNAs and mRNAs and random forest variable hunting, a risk-score model was developed and was further validated in another three independent datasets. Furthermore, the risk score is independent of other clinicopathological observations and performs better at survival-prediction than other clinical characteristics.
The clinical outcome of HNSC carcinoma is affected by the heterogeneity of cancer, treatment method and surgery, the latter of which is controllable, while heterogeneity. Therefore, it is important to elucidate the molecular mechanisms underlying the heterogeneity of HNSC carcinoma (27) . Clinically, HNSC may result from multiple causes, including smoking, HPV infection and diet, which makes the survival-prediction of HNSC difficult to determine using clinicopathological observations. Another indication of this heterogeneity is that no single gene was associated with survival in all datasets used in the present study. On the other hand, a multigene-based model is more robust in predicting prognosis, according to previous studies (24, (28) (29) (30) (31) . lncRNAs and mRNAs are notable regulators of carcinogenesis and cancer development (32, 33) .
However, there are limitations to the present study. To begin with, owing to the retrospective nature of the study, important clinical indictors, including the resection margin of surgery and the drugs used during the therapeutic period, were not available. Secondly, although the risk score is an independent prognostic factor, pooled data were required to facilitate its utilization.
In summary, the 17 lncRNA-mRNA-based model is robust across different platforms and is a better survival predictor than other factors.
